Apixaban Intermediate CAS 545445-44-1 Ịdị ọcha>98.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd bụ onye na-emepụta 3-Morpholino-1- (4- (2-Oxopiperidin-1-yl) phenyl) -5,6-Dihydropyridin-2 (1H) -otu (CAS: 545445). -44-1) na elu mma, etiti nke Apixaban (CAS: 503612-47-3).Ruifu Chemical nwere ike ịnye nnyefe zuru ụwa ọnụ, ọnụahịa asọmpi, ọrụ magburu onwe ya, obere na nnukwu ọnụọgụ dị.Ịzụta Apixaban Intermediates,Please contact: alvin@ruifuchem.com
Aha Chemical | 3-Morpholino-1- (4- (2-Oxopiperidin-1-yl) phenyl) -5,6-Dihydropyridin-2 (1H) -otu. |
Ụdị okwu | Apixaban Intermediate 1;5,6-Dihydro-3- (4-Morpholinyl) -1- [4- (2-Oxo-1-Piperidinyl) phenyl] -2 (1H) -Pyridinone;5-Morpholin-4-yl-1-[4- (2-Oxopiperidin-1-yl) phenyl] -2,3-Dihydropyridin-6-otu;Apixaban Impurity A |
Ọnọdụ Ahịa | Na ngwaahịa, Mmepụta Azụmahịa |
Nọmba CAS | 545445-44-1 |
Usoro ihe omimi | C20H25N3O3 |
Ibu molekụla | 355.43 g/mol |
Ebe Na-agbaze | > 199 ℃ (Dec.) |
Njupụta | 1.267 g/mL |
COA & MSDS | Dị |
Mmalite | Shanghai, China |
Otu | Ọkara nke Apixaban (CAS: 503612-47-3) |
Ụdị | Ruifu Chemical |
Ihe | Nkọwapụta | Nsonaazụ |
Ọdịdị | Ntụ ntụ edo edo dị ọkụ | Ntụ ntụ edo edo dị ọkụ |
Ọnwụ na ihicha | <0.50% | 0.16% |
Ihe fọdụrụ na mgbanye | <0.20% | 0.07% |
Ụzọ ịdị ọcha / nyocha | > 98.0% (HPLC Mpaghara) | 99.12% |
Ọdịghị ọcha nke Onye ọ bụla | <0.50% | <0.50% |
Mgbakọta adịghị ọcha | <2.00% | 0.88% |
1H NMR Spectrum | Nkwekọ na Structure | Dabara |
LC-MS maka njirimara | Dabara | Dabara |
Mmechi | A nwalela ngwaahịa a wee kwado nkọwa ndị enyere | |
Ngwa | Ọkara nke Apixaban (CAS: 503612-47-3) |
ngwugwu:Fluorinated Bottle, Aluminom foil bag, 25kg / Cardboard Drum, ma ọ bụ dị ka ndị ahịa chọrọ.
Ọnọdụ Nchekwa:Debe akpa ahụ nke ọma ma debe ya n'ụlọ nkwakọba ihe dị jụụ, kpọrọ nkụ na nke ikuku na-ekpo ọkụ n'ebe ihe na-adabaghị adaba.Chebe site na ìhè na mmiri mmiri.
Mbupu:Jiri ikuku na-ebuga ụwa niile site na FedEx / DHL Express.Nye nnyefe ngwa ngwa na ntụkwasị obi.
Kedu ka esi azụta?Biko kpọtụrụDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
Ahụmịhe afọ 15?Anyị nwere ihe karịrị 15 afọ nke ahụmahụ na mmepụta na mbupụ nke a dịgasị iche iche nke elu mma pharmaceutical intermediates ma ọ bụ ezi kemịkal.
Isi ahịa?Na-ere ahịa ụlọ, North America, Europe, India, Korea, Japanese, Australia, wdg.
Uru?Ogo kachasị elu, ọnụ ahịa dị ọnụ ala, ọrụ ọkachamara na nkwado teknụzụ, nnyefe ngwa ngwa.
OgoNkwenye?Usoro njikwa mma siri ike.Ngwá ọrụ ọkachamara maka nyocha gụnyere NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, wdg.
Ihe atụ?Ọtụtụ ngwaahịa na-enye ihe nlele efu maka nyocha dị mma, ndị ahịa kwesịrị ịkwụ ụgwọ mbupu.
Nyocha ụlọ ọrụ?Nnabata nyocha ụlọ ọrụ.Biko mee oge oge tupu oge eruo.
MOQ?Enweghị MOQ.A na-anabata obere usoro.
Oge Mbuga ozi? Ọ bụrụ n'ime ngwaahịa, ekwenyere nnyefe ụbọchị atọ.
Ụgbọ njem?Site Express (FedEx, DHL), nke ikuku, site n'oké osimiri.
Akwụkwọ?Mgbe ọrụ ahịa gasịrị: COA, MOA, ROS, MSDS, wdg nwere ike ịnye.
Synthesis omenala?Nwere ike ịnye ọrụ nhazi ahaziri iche ka ọ dabara mkpa nyocha gị nke ọma.
Usoro ịkwụ ụgwọ?A ga-ebu ụzọ ziga akwụkwọ ọnụahịa Proforma mgbe nkwenye nke iwu, kpuchiri ozi ụlọ akụ anyị.Ịkwụ ụgwọ site na T/T (Telex Nyefee), PayPal, Western Union, wdg.
3-Morpholino-1- (4- (2-Oxopiperidin-1-yl) phenyl) -5,6-Dihydropyridin-2 (1H) -otu (CAS: 545445-44-1) bụ etiti nke Apixaban (CAS: 503612-47-3).
Apixaban bụ ụdị ọhụrụ nke inhibitor Xa factor inhibitor nke Bristol-Myers Squibb na Pfizer mebere.Aha ahia a bu Eratol, nke bu udi ohuru nke anticoagulant nke onu.Site na igbochi ihe dị mkpa coagulation Xa, Apixaban nwere ike igbochi mmepụta thrombin na thrombosis.Na Eprel 26, 2007, Bristol-Myers Squibb sonyeere Pfizer aka ikwusa nkwado na mmepe nke ọhụrụ anticoagulant Apixaban nke Bristol-Myers Squibb nwere dị ka ihe nkwalite ọzọ na Warfarin.Na May 2011, Apixaban bụ onye mbụ kwadoro mgbochi nke thrombosis venous na ndị ọrịa toro eto na-ahọrọ ịwa ahụ hip ma ọ bụ ikpere na mba 27 EU, Iceland na Norway.Na Nọvemba 20, 2012, European Commission kwadoro Ererto (Apixaban) maka igbochi ọrịa strok na usoro embolism na ndị okenye na-arịa ọrịa na-adịghị valvular atrial fibrillation (NVAF) na otu ma ọ bụ karịa ihe ize ndụ.N'ikpeazụ, Canadian Food and Drug Administration, Japan, na US FDA kwadoro Ererto (Apixaban) maka mgbochi nke ọrịa strok na embolism systemic na ndị ọrịa toro eto na-enweghị valvular atrial fibrillation (NVAF) nwere otu ma ọ bụ karịa ihe ize ndụ.N'April 12, 2013, a mara ọkwa ọkwa ọgwụ ọhụrụ anticoagulant Eloto (ELIQUIS)(Apixaban) nke Bristol-Myers Squibb na Pfizer jikọrọ aka na a ga-edepụta ya na China.